ReviewDermatology and therapy2024

Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review.

Miguel Mansilla-Polo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.